Custom Antibody Market Size, Trends and Growth Analysis by 2027

The custom antibody market is projected to reach a valuation of US$ 833.71 million by 2028, up from US$ 409.26 million in 2021, reflecting a compound annual growth rate (CAGR) of 10.7% from 2021 to 2028.

Several factors are propelling the growth of the custom antibody market. These include a significant demand for research applications, increasing governmental support, evolving disease profiles, a rise in public-private partnerships, and enhanced funding activities that are collectively boosting the biotechnology sector's performance. However, the production processes for monoclonal and polyclonal antibodies differ based on the animal sources used for their derivation. Additionally, the pricing of custom antibodies is influenced by the specific packages offered for various applications, which can pose challenges to market expansion.

Biotechnology firms are increasingly prioritizing collaborations, partnerships, acquisitions, and financial support to advance their market positions. Numerous companies are actively providing research and development services tailored to custom antibodies. The COVID-19 pandemic has also opened up new avenues for strategic decision-making among industry players. For instance, in January 2021, Morphic Therapeutic, a biotechnology firm, entered into a collaboration with Janssen Pharmaceutical, Inc., a subsidiary of Johnson & Johnson Private Limited, to create innovative antibodies targeting third integrin proteins, which are a family of widely distributed receptors. In March 2021, Y-Biologics, a South Korean entity, and Pierre Fabre, a French company, announced a strategic research collaboration and optional licensing agreement aimed at developing targets for immune-oncology. They commenced testing Y-Biologic's monoclonal antibodies against a specific tumor microenvironment (TME) target selected by Pierre Fabre. Furthermore, in June 2021, GenScript unveiled its MonoRab service, which focuses on custom rabbit monoclonal antibodies (mABs). This service is part of GenScript's comprehensive premium antibody offerings and employs proprietary hybridoma technologies along with early-stage monoclonal antibody sequencing to produce custom rabbit mAbs that exhibit enhanced specificity, higher affinity, and a diverse range of capabilities suitable for various applications. The collaboration between these companies is expected to last for three years, with a potential two-year extension thereafter.

The global custom antibody market is categorized by service, type, source, research area, and end users. In terms of service, the market is divided into antibody development, antibody production and purification, and antibody fragmentation and labeling. In 2020, the antibody development segment commanded the largest market share and is anticipated to experience significant growth during the forecast period. Regarding type, the market is segmented into monoclonal antibodies, polyclonal antibodies, and other custom antibodies. The monoclonal antibodies segment held the largest market share in 2020, while the polyclonal antibodies segment is expected to see growth in the upcoming years. When considering the source, the custom antibodies are categorized into mice, rabbits, and others, with the mice segment holding the largest market share in 2020 and projected to achieve the highest CAGR during the forecast period.

In terms of research areas, the custom antibody market is divided into oncology, immunology, stem cells, infectious diseases, neurobiology, cardiovascular diseases, and others. The oncology segment was the largest in 2020, while the stem cells segment is expected to grow at the fastest rate in the coming years. As for end users, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutions, and contract research organizations. The pharmaceutical and biotechnology companies segment held the largest market share in 2020 and is expected to grow at the fastest pace in the near future.

Key primary and secondary sources referenced in this report include the Food and Drug Administration, World Health Organization (WHO), Organization for Economic Co-operation and Development, and the Center for Disease Dynamics, Economics, and Policy (CDEEP), among others.